CC-10004 trial (I would apply)

Male pelvic pain, prostatitis, IC
gmccormack
Veteran
Veteran
Posts: 204
Joined: Wed Jan 21, 2009 3:19 am
Location: Boston, MA

CC-10004 trial (I would apply)

Post by gmccormack »

Anyone here from Michigan or surrounding area?

New trial to test efficacy of CC-10004, they are still accepting. I would love to take part in this one, you get full genetic workup and surely be treated by a dr who specializes in proteotics.

http://www.clinicaltrials.gov/ct2/show/ ... tis&rank=2


Here's an old trial for CC-10004 used to see the results on cytokines.

The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures


Myeloma cells and human umbilical vein endothelial cells (HUVECs) were co-cultured to model in vitro the interactions between myeloma and endothelium, and treated with thalidomide and two selective cytokine inhibitory drugs (SelCIDs, phosphodiesterase-4 inhibitors). Flow cytometry and enzyme-linked immunosorbent assay were used to assess production of two key cytokines – vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) – and apoptosis in co-cultured HUVECs and myeloma cells. VEGF was produced by both myeloma cells and HUVECs, while IL-6 was almost exclusively produced by endothelial cells. In co-culture, there was significant up-regulation of VEGF and IL-6 production compared with the sum of separate myeloma and endothelial cell cultures. SelCIDs markedly inhibited production of both cytokines in co-cultures, with CC-10004 being more potent than CC-1088. In addition, SelCIDs induced myeloma cell apoptosis. Apoptosis in co-cultured myeloma cells was significantly lower than in those cultured separately, suggesting that co-culture partially protected myeloma cells from drug-induced apoptosis. This protective effect was probably due to IL-6 produced by endothelial cells in co-culture as addition of anti-IL-6 neutralizing antibody, but not anti-VEGF antibody, abrogated it. In conclusion, SelCIDs can exert their anti-myeloma activity through two mechanisms, i.e. inhibition of VEGF and IL-6 production by interacting myeloma and endothelium and induction of myeloma cell apoptosis.
Age: | Onset Age: | Symptoms: | Helped By: | Worsened By: | Other comments: